The assumption of the efficacy of mTORi in this indication may be reasonable considering the dysregulation of mTOR pathway in CRs in patients with TSC and reported efficacy of mTORi in the treatment of other tumorous TSC manifestations [12,13,14,15,16,17,18,20]. The gene discussed is MTOR; the disease is tuberous sclerosis.